[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649304":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":31,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":20,"maxAge":20,"enrollmentInfo":45,"targetDuration":20,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":20,"overallStatus":54,"whyStopped":20,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":20},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Standardized note with standard-of-care pharmacist support","EXPERIMENTAL","Standardized progress note templates with opt-in option for standard-of-care pharmacist support of ropeginterferon alfa-2b titration",[13],"Behavioral: Standardized progress note",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Standardized progress note","Pilot intervention will include a standardized progress note for PV patient visits in addition to a standard-of-care opt-in for pharmacist-led titration for patients on ropeginterferon alfa-2b.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Michelle Lee, MD","CONTACT","617-882-6060","mlee37@mgb.org",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Michelle Lee","Principal Investigator",[32],{"name":33,"class":34},"PharmaEssentia","INDUSTRY","100649304","standardized-documentation-and-assessments-for-polycythemia-vera-a-quality-improvement-initiative-100649304",false,"NCT07734272","Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative","STANDARDIZEd Documentation and Assessments for Polycythemia Vera (STANDARDIZE-PV): A Quality Improvement Initiative","STANDARDIZE-PV","Inclusion Criteria:\n\n\\- Hematologists and medical oncologists within the Mass General Brigham network sites who treat at least one patient with PV in their outpatient clinic.\n\nExclusion Criteria:\n\n* Clinicians who do not have an outpatient hematology or medical oncology clinic within Mass General Brigham.\n* Clinicians who do not utilize the EPIC electronic medical record (EMR) System as their method of patient progress note documentation.",true,"ALL",{"count":46,"type":47},32,"ESTIMATED","INTERVENTIONAL",[50],"NA","The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative ropeginterferon alfa-2b titration service is feasible, acceptable, and appropriate for clinicians who manage PV.",[53],"Polycythemia Vera","NOT_YET_RECRUITING","2026-07-24",{"date":57,"type":58},"2026-07-29","ACTUAL",{"date":60,"type":47},"2026-08-05",{"date":62,"type":47},"2028-03-31",{"name":5,"class":6}]